FDA Adverse Event Injury Summary report: N

SURGICEL ABSORBABLE HEMOSTAT

MDR report key: 2860843 · Received December 6, 2012

Report

Report Number
2210968-2012-07943
Event Type
Injury
Date Received
December 6, 2012
Date of Event
November 13, 2012
Report Date
November 19, 2012
Manufacturer
ETHICON, INC.
Product Code
LMG
PMA / PMN Number
N12159
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). CONCLUSION: THE PRODUCT UPON WHICH THIS MEDWATCH IS BASED IS ANTICIPATED. ONCE THE PRODUCT IS RECEIVED, ANY FURTHER INFORMATION DERIVED FROM THE EVALUATION WILL BE SUBMITTED IN A SUPPLEMENTAL 3500A FORM. IN ADDITION, A REVIEW OF THE BATCH MANUFACTURING RECORDS WAS CONDUCTED AND THE BATCH MET ALL FINISHED GOODS RELEASE CRITERIA.

Additional Manufacturer Narrative · 1

(B)(4). CONCLUSION: NO CONCLUSION CAN BE DRAWN AT THIS TIME. SHOULD ADDITIONAL INFORMATION BE OBTAINED, A SUPPLEMENTAL 3500A FORM WILL BE SUBMITTED ACCORDINGLY. ONE UNOPENED REPRESENTATIVE SAMPLE WAS VISUAL EXAMINATION. THE FOIL POUCH REVEALED THAT THERE WAS A TEAR ON THE UPPER RIGHT CORNER OF THE POUCH AND ANOTHER TEAR IN THE BOTTOM LEFT CORNER OF THE POUCH. THE TEARS SEEM TO BE RELATED TO AN ATTEMPT TO OPEN THE FOIL POUCH OR PRODUCT HANDLING SUBSEQUENT TO THE MANUFACTURING OF THE PRODUCT. THE EVALUATION BEING PERFORMED IS OF A REPRESENTATIVE SAMPLE. THE CONDITION OF THE FOIL POUCH USED ON THE OPERATION IS NOT KNOWN.

Description of Event or Problem · 1

IT WAS REPORTED THAT A PATIENT UNDERWENT A RESECTION OF A SMALL HEPATOCELLULAR CARCINOMA ON (B)(6) 2012 AND AN ABSORBABLE HEMOSTATIC AGENT WAS USED. AFTER THE FIRST POST OPERATIVE DAY THE PATIENT DEVELOPED A FEVER AND YELLOW DRAINAGE. THE SURGEON DRAINED THE FLUID THROUGH DRAINAGE TUBE. THE PATIENT IS NOW IN GOOD CONDITION. ADDITIONAL INFORMATION HAS BEEN REQUESTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 SURGICEL ABSORBABLE HEMOSTAT HEMOSTATIC AGENT, ABSORBABLE LMG ETHICON, INC. NA EDB175-1

Patients

Seq Age Sex Outcome Treatment
1 40 YR Required Intervention